BR112021007788A8 - Composto inibidor de jak 2-azabiciclo hexano - Google Patents

Composto inibidor de jak 2-azabiciclo hexano

Info

Publication number
BR112021007788A8
BR112021007788A8 BR112021007788A BR112021007788A BR112021007788A8 BR 112021007788 A8 BR112021007788 A8 BR 112021007788A8 BR 112021007788 A BR112021007788 A BR 112021007788A BR 112021007788 A BR112021007788 A BR 112021007788A BR 112021007788 A8 BR112021007788 A8 BR 112021007788A8
Authority
BR
Brazil
Prior art keywords
jak
compound
azabicyclohexane
inhibitor compound
inhibitor
Prior art date
Application number
BR112021007788A
Other languages
English (en)
Other versions
BR112021007788A2 (pt
Inventor
Lan Jiang
R Fatheree Paul
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of BR112021007788A2 publication Critical patent/BR112021007788A2/pt
Publication of BR112021007788A8 publication Critical patent/BR112021007788A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

composto inibidor de jak 2-azabiciclo hexano. a invenção fornece um composto de fórmula 1 ou um sal farmaceuticamente aceitável deste, que é útil como um inibidor de jak. a invenção também fornece composições farmacêuticas compreendendo o composto, métodos de uso do composto para tratar doenças suscetíveis a um inibidor de jak e processos úteis para preparar o composto.
BR112021007788A 2018-10-29 2019-10-18 Composto inibidor de jak 2-azabiciclo hexano BR112021007788A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751967P 2018-10-29 2018-10-29
US62/751,967 2018-10-29
PCT/US2019/056947 WO2020092019A1 (en) 2018-10-29 2019-10-18 2-azabicyclo hexane compound as jak inhibitor

Publications (2)

Publication Number Publication Date
BR112021007788A2 BR112021007788A2 (pt) 2021-07-27
BR112021007788A8 true BR112021007788A8 (pt) 2022-04-26

Family

ID=68542755

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021007788A BR112021007788A8 (pt) 2018-10-29 2019-10-18 Composto inibidor de jak 2-azabiciclo hexano

Country Status (12)

Country Link
US (2) US10968222B2 (pt)
EP (1) EP3853229A1 (pt)
JP (1) JP2022506111A (pt)
KR (1) KR20210084512A (pt)
CN (1) CN112955451A (pt)
AU (1) AU2019373059A1 (pt)
BR (1) BR112021007788A8 (pt)
CA (1) CA3113667A1 (pt)
IL (1) IL282460A (pt)
MX (1) MX2021004582A (pt)
SG (1) SG11202103042XA (pt)
WO (1) WO2020092019A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10100049B2 (en) 2015-11-03 2018-10-16 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
MX2017011630A (es) 2016-09-08 2018-09-25 Foamix Pharmaceuticals Ltd Composiciones y metodos para tratar rosacea y acne.
PL3837258T3 (pl) 2018-09-04 2024-09-16 Theravance Biopharma R&D Ip, Llc Amidy dimetyloaminoazetydyny jako inhibitory jak
SG11202101785UA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc Process for preparing jak inhibitors and intermediates thereof
BR112021004063A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN111620868B (zh) * 2020-05-28 2021-08-31 爱斯特（成都）生物制药股份有限公司 一种1H-吡唑并[3,4-b]吡啶-3-甲醛的制备方法
CN111973599A (zh) * 2020-08-07 2020-11-24 杭州邦顺制药有限公司 用于眼部疾病治疗的化合物
EP4196477A4 (en) * 2020-08-17 2024-10-09 Vyne Therapeutics Inc ANHYDROUS ELASTOMER GEL FORMULATIONS CONTAINING TOFACITINIB
CN117813298A (zh) * 2021-06-25 2024-04-02 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑吲唑化合物
CN114181055A (zh) * 2021-12-21 2022-03-15 苏州楚凯药业有限公司 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法
CN115969796B (zh) * 2022-12-06 2024-07-09 苏州大学 一种jak抑制剂长效微球及其制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
JP5651681B2 (ja) 2009-04-03 2015-01-14 大日本住友製薬株式会社 代謝型グルタミン酸受容体５介在障害の治療のための化合物、およびその使用方法
CA2785037C (en) 2009-12-21 2018-01-16 Samumed, Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
JP6192839B2 (ja) 2013-12-05 2017-09-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド
WO2015173683A1 (en) 2014-05-14 2015-11-19 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
EP3371185B1 (en) * 2015-11-03 2020-09-30 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EP3865481A1 (en) * 2015-11-03 2021-08-18 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
US10100049B2 (en) * 2015-11-03 2018-10-16 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
ES2882186T3 (es) 2017-03-09 2021-12-01 Theravance Biopharma R&D Ip Llc Inhibidores de JAK que contienen una amida heterocíclica de 4 miembros
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
AU2018261591B2 (en) 2017-05-01 2021-09-02 Theravance Biopharma R&D Ip, Llc Crystalline forms of a JAK inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
PT3932919T (pt) 2019-02-25 2024-07-30 Henan Medinno Pharmaceutical Tech Co Ltd Composto inibidor de jak e sua utilização
MA55201A (fr) 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途

Also Published As

Publication number Publication date
IL282460A (en) 2021-06-30
CA3113667A1 (en) 2020-05-07
KR20210084512A (ko) 2021-07-07
US20200131178A1 (en) 2020-04-30
BR112021007788A2 (pt) 2021-07-27
WO2020092019A1 (en) 2020-05-07
US10968222B2 (en) 2021-04-06
US20210206764A1 (en) 2021-07-08
MX2021004582A (es) 2021-06-15
CN112955451A (zh) 2021-06-11
AU2019373059A1 (en) 2021-05-06
JP2022506111A (ja) 2022-01-17
EP3853229A1 (en) 2021-07-28
SG11202103042XA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
DOP2020000083A (es) Compuesto de pirimidina como inhibidor de las janocinasas
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
PH12021550388A1 (en) Process for preparing jak inhibitors and intermediates thereof
BR112017011316A2 (pt) derivados heterocíclicos e uso destes
CL2018003431A1 (es) Tratamiento de la enfermedad de parkinson.
BR112021011325A2 (pt) Derivados de rapamicina
EA202191188A1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
MX2019002104A (es) Compuesto de 3-piridiloxifenildihidrouracilo y su uso.
BR112018076564A2 (pt) uso de um composto de fórmula i, composições farmacêuticas, composto de fórmula i, usos de um composto ou um sal farmaceuticamente aceitável do mesmo, e compostos ou sais farmaceuticamente aceitáveis dos mesmos
BR112017021589A2 (pt) métodos para o tratamento de transtornos cardiovasculares

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements